BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18425807)

  • 1. Controlled release of repifermin from polyelectrolyte complexes stimulates endothelial cell proliferation.
    Huang M; Berkland C
    J Pharm Sci; 2009 Jan; 98(1):268-80. PubMed ID: 18425807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor.
    Huang M; Vitharana SN; Peek LJ; Coop T; Berkland C
    Biomacromolecules; 2007 May; 8(5):1607-14. PubMed ID: 17428030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells.
    Alderson R; Gohari-Fritsch S; Olsen H; Roschke V; Vance C; Connolly K
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):202-12. PubMed ID: 12203102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of repifermin (keratinocyte growth factor-2) against abnormalities in gastrointestinal mucosal transport in a murine model of colitis.
    Greenwood-Van Meerveld B; Venkova K; Connolly K
    J Pharm Pharmacol; 2003 Jan; 55(1):67-75. PubMed ID: 12625869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers.
    Robson MC; Phillips TJ; Falanga V; Odenheimer DJ; Parish LC; Jensen JL; Steed DL
    Wound Repair Regen; 2001; 9(5):347-52. PubMed ID: 11896977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of polyanions on the structure and stability of repifermin (keratinocyte growth factor-2).
    Derrick T; Grillo AO; Vitharana SN; Jones L; Rexroad J; Shah A; Perkins M; Spitznagel TM; Middaugh CR
    J Pharm Sci; 2007 Apr; 96(4):761-76. PubMed ID: 17094125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncovalent PEGylation by polyanion complexation as a means to stabilize keratinocyte growth factor-2 (KGF-2).
    Khondee S; Olsen CM; Zeng Y; Middaugh CR; Berkland C
    Biomacromolecules; 2011 Nov; 12(11):3880-94. PubMed ID: 21954860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
    Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Sandborn WJ; Sands BE; Wolf DC; Valentine JF; Safdi M; Katz S; Isaacs KL; Wruble LD; Katz J; Present DH; Loftus EV; Graeme-Cook F; Odenheimer DJ; Hanauer SB
    Aliment Pharmacol Ther; 2003 Jun; 17(11):1355-64. PubMed ID: 12786629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.
    Sung C; Parry TJ; Riccobene TA; Mahoney A; Roschke V; Murray J; Gu ML; Glenn JK; Caputo F; Farman C; Odenheimer DJ
    AAPS PharmSci; 2002; 4(2):E8. PubMed ID: 12102617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
    Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
    Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological and growth responses of vascular smooth muscle and endothelial cells cultured on immobilized heparin and dextran sulfate surfaces.
    Robu IS; Walters HL; Matthew HWT
    J Biomed Mater Res A; 2017 Jun; 105(6):1725-1735. PubMed ID: 28198136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adhesion, proliferation, and gene expression profile of human umbilical vein endothelial cells cultured on bilayered polyelectrolyte coatings composed of glycosaminoglycans.
    Heng BC; Bezerra PP; Meng QR; Chin DW; Koh LB; Li H; Zhang H; Preiser PR; Boey FY; Venkatraman SS
    Biointerphases; 2010 Sep; 5(3):FA53-62. PubMed ID: 21171714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-functionalized chitosan-alginate scaffolds for controlled release of growth factor.
    Ho YC; Mi FL; Sung HW; Kuo PL
    Int J Pharm; 2009 Jul; 376(1-2):69-75. PubMed ID: 19450670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains.
    Zhang W; Swanson R; Xiong Y; Richard B; Olson ST
    J Biol Chem; 2006 Dec; 281(49):37302-10. PubMed ID: 17040907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repifermin. Human Genome Sciences/GlaxoSmithKline.
    Wheeler G
    IDrugs; 2001 Jul; 4(7):813-9. PubMed ID: 15995938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The covalently immobilized antimicrobial peptide LL37 acts as a VEGF mimic and stimulates endothelial cell proliferation.
    Szulcek R; Bollensdorff C; Hordijk P; Gabriel M
    Biochem Biophys Res Commun; 2018 Feb; 496(3):887-890. PubMed ID: 29366792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release of human platelet lysate growth factors by thermosensitive hydroxybutyl chitosan hydrogel promotes skin wound healing in rats.
    Lim T; Tang Q; Zhu Z; Wei X; Zhang C
    J Biomed Mater Res A; 2020 Oct; 108(10):2111-2122. PubMed ID: 32323472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled delivery of the heparan sulfate/FGF-2 complex by a polyelectrolyte scaffold promotes maximal hMSC proliferation and differentiation.
    Calarco A; Petillo O; Bosetti M; Torpedine A; Cannas M; Perrone L; Galderisi U; Melone MA; Peluso G
    J Cell Biochem; 2010 Jul; 110(4):903-9. PubMed ID: 20564189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomimetic proteoglycan nanoparticles for growth factor immobilization and delivery.
    Zandi N; Mostafavi E; Shokrgozar MA; Tamjid E; Webster TJ; Annabi N; Simchi A
    Biomater Sci; 2020 Feb; 8(4):1127-1136. PubMed ID: 31389409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.